INS and metabolic syndrome: Interestingly, both GR and ZBTB16 are linked to metabolic syndrome including changes in insulin sensitivity (57), raising the possibility that the severe metabolic side effects experienced by patients undergoing long-term GC treatment could involve mis-regulation of ZBTB16 as a result of repeatedly prolonged GR activation.